Director/PDMR Shareholding 26 February 2026
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Analytical Bioventures S.C.A (RCS B89265) 23, Va Fleuri, L-1526 Luxembourg |
2. | Reason for the notification | |
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
b) | Initial notification / amendment | Initial |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 67.484100 | 1000 | ||
d) | Aggregated information
| ||
1000 | |||
EUR 67,484.10 | |||
e) | Date of the transaction | 2026-02-20 | |
f) | Place of the transaction | XPAR | |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Analytical Bioventures S.C.A (RCS B89265) 23, Va Fleuri, L-1526 Luxembourg |
2. | Reason for the notification | |
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
b) | Initial notification / amendment | Initial |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 66.970200 | 1000 | ||
d) | Aggregated information
| ||
1000 | |||
EUR 66,970.20 | |||
e) | Date of the transaction | 2026-02-23 | |
f) | Place of the transaction | XPAR | |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Analytical Bioventures S.C.A (RCS B89265) 23, Va Fleuri, L-1526 Luxembourg |
2. | Reason for the notification | |
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
b) | Initial notification / amendment | Initial |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 66.823500 | 1000 | ||
d) | Aggregated information
| ||
1000 | |||
EUR 66,823.50 | |||
e) | Date of the transaction | 2026-02-24 | |
f) | Place of the transaction | XPAR | |
1. | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Analytical Bioventures S.C.A (RCS B89265) 23, Va Fleuri, L-1526 Luxembourg |
2. | Reason for the notification | |
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
b) | Initial notification / amendment | Initial |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 67.288900 | 1000 | ||
d) | Aggregated information
| ||
1000 | |||
EUR 67,288.90 | |||
e) | Date of the transaction | 2026-02-25 | |
f) | Place of the transaction | XPAR | |
For more information, please visit https://www.eurofins.com or contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
About Eurofins - the global leader in bio-analysisEurofins is Testing for Life. With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
Attachments
- Original document
- Permalink
Disclaimer
Eurofins Scientific SE published this content on February 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on February 26, 2026 at 13:47 UTC.
